Does Sharp Health Plan Cover Dupixent?

What Is Dupixent and Why Does Coverage Get Complicated?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the interleukin-4 receptor alpha (IL-4Rα) subunit, suppressing both IL-4 and IL-13 signaling. The FDA first approved it in March 2017 for adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies. Since then, approvals have expanded to eosinophilic esophagitis, moderate-to-severe asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, and, as of May 2024, atopic dermatitis in patients as young as 1 year old. [1]

Because Dupixent carries a list price of roughly $3,700, $4,100 per month, insurers including Sharp Health Plan require prior authorization (PA) before they will pay for it. PA is not a denial; it is a documented clinical review process. Getting it right the first time saves weeks of delay.

How Dupixent Works Clinically

Dupixent targets the shared receptor component used by both IL-4 and IL-13, two cytokines central to type 2 inflammatory pathways. In the key SOLO-1 and SOLO-2 trials (combined N=1,379), 37 to 38% of patients receiving dupilumab 300 mg every other week achieved an IGA score of 0 or 1 (clear or almost clear skin) at week 16, compared with 8 to 10% on placebo (P<0.001). [2] Those numbers are what make Dupixent medically necessary for many patients, and they are exactly the clinical evidence your prescriber should reference in a PA request.

Why Sharp Health Plan Requires Prior Authorization

Sharp Health Plan is a nonprofit HMO operating exclusively in San Diego County. Like virtually all commercial insurers, it places high-cost specialty biologics on a non-preferred specialty tier that requires PA. The core reason is cost management: specialty drugs accounted for 50% of total US drug spending in 2022 despite representing fewer than 2% of prescriptions, according to the IQVIA Institute. [3] Prior authorization is also used to confirm the diagnosis matches an FDA-approved indication and that the prescribing physician has documentation to support medical necessity.

Sharp Health Plan Formulary Placement for Dupixent

Sharp Health Plan's commercial formulary places Dupixent on a specialty or Tier 4/5 drug tier, subject to prior authorization and, in most plan designs, step therapy requirements. The exact tier and cost-share percentage varies by whether you hold an individual, employer-sponsored, or Covered California plan through Sharp.

Specialty Tier Cost-Sharing

On most Sharp commercial plans, Tier 5 specialty drugs carry a coinsurance of 20 to 30% after the deductible is met, rather than a flat copay. On a $4,000/month drug, 20% coinsurance equals $800 per month out of pocket before any assistance. Dupixent MyWay, Sanofi's patient support program, can reduce that to $0 per month for commercially insured patients who meet income thresholds. [4]

For Sharp's Medicare Advantage plans, Part D coverage applies. Under the Inflation Reduction Act of 2022, Part D out-of-pocket drug costs are capped at $2,000 per year beginning January 1, 2025, which substantially changes the cost calculus for Medicare beneficiaries on Dupixent. [5]

Medi-Cal Through Sharp

Sharp Community Medical Group contracts with Medi-Cal managed care in San Diego. Medi-Cal covers Dupixent for atopic dermatitis under the Department of Health Care Services Drug Formulary, but a separate PA process applies and step therapy timelines can be longer. Confirm your specific coverage by calling the member services number on the back of your Sharp ID card.

Prior Authorization Requirements for Dupixent Under Sharp Health Plan

Sharp Health Plan's PA criteria for Dupixent generally mirror the clinical criteria established by Magellan Rx or CVS Caremark, depending on which pharmacy benefit manager (PBM) administers Sharp's specialty drug benefit in a given plan year.

Typical Documentation Required

Your prescriber will need to submit:

• A confirmed diagnosis of the FDA-approved indication (e.g., atopic dermatitis ICD-10: L20.9)
• Disease severity documentation (IGA score of 3 or 4, or EASI score ≥16, or SCORAD ≥25 for moderate-to-severe classification)
• Documented trial and failure of at least two topical therapies, most commonly a mid-to-high potency topical corticosteroid (e.g., triamcinolone 0.1% or fluocinolone 0.025%) and a topical calcineurin inhibitor (tacrolimus 0.1% or pimecrolimus 1%) [6]
• Patient age and weight (relevant for pediatric dosing)
• Absence of contraindications to dupilumab

For asthma, additional documentation of baseline eosinophil count (≥150 cells/µL) and uncontrolled symptoms despite medium-to-high dose inhaled corticosteroids is typically required, per the 2023 GINA guidelines. [7]

Step Therapy: What Counts as Failure

Step therapy requires that you actually try cheaper alternatives first. "Failure" is defined as inadequate response after an adequate trial, typically 4 to 8 weeks at an appropriate dose, or documented intolerance or contraindication. You do not need to wait 8 weeks if you develop a serious adverse event (e.g., skin atrophy from prolonged high-potency steroid use). Your dermatologist should note the exact products used, dose, duration, and reason for discontinuation in the PA submission.

California's SB 159 (2019) limits step therapy requirements for commercially insured patients and prohibits insurers from requiring step therapy when the requested drug is FDA-approved for the patient's condition and the prescriber documents that the required step drug is clinically contraindicated or likely to cause an adverse reaction. [8] This is important use if your insurer's step therapy protocol seems excessive.

How to Submit a Prior Authorization for Sharp Health Plan

The PA process has defined steps, and following them precisely reduces rejection rates.

Step 1: Prescriber Submits the PA Request

Your dermatologist, allergist, or pulmonologist initiates the PA by submitting Sharp Health Plan's specialty drug prior authorization form, available on the Sharp Health Plan provider portal. The form requires the clinical information listed above plus an attestation of medical necessity. Electronic submission through the provider portal is faster than fax.

Step 2: Sharp's PBM Reviews the Request

Standard PA review takes 3 to 5 business days. For urgent or expedited requests (when a delay could seriously jeopardize health), Sharp must respond within 72 hours under California Department of Managed Health Care (DMHC) regulations. [9]

Step 3: Approval, Denial, or Additional Information Request

If approved, Sharp will authorize Dupixent for a defined period, typically 12 months, after which reauthorization is required. If denied, you receive a written denial notice with the specific reason and your appeal rights. You have the right to an independent medical review (IMR) through the DMHC.

What to Do If Sharp Health Plan Denies Dupixent

A denial is not the end of the road. Published analysis of specialty drug appeals shows that 40 to 60% of initial denials are overturned on first-level appeal when the prescriber submits additional clinical documentation. Here is the structured path forward.

First-Level Internal Appeal

File within 60 days of the denial notice (check your specific plan documents; timelines vary). Your prescriber should write a detailed letter of medical necessity that directly addresses the denial reason. If Sharp denied because step therapy was not documented, the letter should provide exact product names, dose, dates, and outcome of each prior therapy.

California Independent Medical Review (IMR)

California law gives members the right to request an IMR through the DMHC if Sharp denies or delays care that a physician says is medically necessary. IMR is free, and the DMHC reports that approximately 74% of IMR decisions result in full or partial approval when the submitting physician provides complete clinical documentation. [10] Submit IMR requests at dmhc.ca.gov.

Expedited Review for Urgent Cases

If your condition is severe and deteriorating (e.g., infected eczema covering >30% BSA, oral corticosteroid-dependent asthma), request expedited review. Under 28 CCR §1300.67.2, Sharp must respond to an expedited grievance within 3 business days.

Dupixent Cost Assistance Options When Coverage Is Delayed or Denied

Even while appealing a denial, you can access Dupixent at reduced cost through manufacturer and third-party programs.

Dupixent MyWay (Sanofi/Regeneron)

The Dupixent MyWay program offers commercially insured patients a copay card that caps monthly out-of-pocket costs at $0 for eligible patients. Enrollment is online at dupixent.com or by calling 1-844-DUPIXENT. Income limits apply for uninsured patients seeking free drug. [4]

Patient Assistance Program (PAP)

Sanofi's PAP provides Dupixent at no cost to uninsured or underinsured patients who meet income criteria (generally household income at or below 400% of the federal poverty level). Applications are processed within 5 to 7 business days.

Bridge Therapy While Appealing

Your dermatologist may prescribe a medium-potency topical corticosteroid such as triamcinolone acetonide 0.1% cream plus an oral antihistamine for symptom control during the PA or appeal period. For severe refractory cases, short-course oral prednisone (0.5 mg/kg/day for 5 to 7 days) can provide temporary relief while the biologic authorization is pending, though repeated systemic corticosteroid use is associated with cumulative adverse effects including adrenal suppression. [11]

Clinical Evidence Supporting Dupixent Medical Necessity

When Sharp Health Plan or its PBM reviews your PA or appeal, the strength of the clinical evidence supporting Dupixent's effectiveness matters. Here are the key trials your prescriber should cite.

Atopic Dermatitis: SOLO-1 and SOLO-2

The SOLO-1 and SOLO-2 trials (combined N=1,379) were phase 3, randomized, double-blind, placebo-controlled studies. At week 16, 36.8 to 38% of patients receiving dupilumab 300 mg every other week achieved IGA 0/1, versus 8.5 to 10% with placebo (P<0.001). [2] Mean EASI score improved by 72 to 74% from baseline in the dupilumab group.

Pediatric Atopic Dermatitis: LIBERTY AD PEDS

The LIBERTY AD PEDS trial enrolled 367 adolescents (aged 12 to 17) with moderate-to-severe atopic dermatitis. At week 16, 24% of dupilumab patients achieved IGA 0/1 versus 2% of placebo patients (P<0.001), and 41.5% achieved EASI-75 (75% reduction in EASI score) versus 8.1% with placebo. [12] This trial directly supports PA requests for adolescent patients on Sharp plans.

Asthma: QUEST Trial

The QUEST trial (N=1,902) demonstrated that dupilumab 200 mg or 300 mg every other week reduced severe asthma exacerbations by 47.7% over 52 weeks in patients with baseline blood eosinophils of 300 cells/µL or more, versus placebo (P<0.001). [13] If your Sharp plan denied Dupixent for asthma, this trial is the primary citation for your appeal.

How the HealthRX Team Approaches Dupixent PA Navigation

The HealthRX clinical team developed a four-step PA navigation framework for biologics on restrictive formularies:

Step 1: Pre-submission audit. Before the PA is filed, verify that the medical record contains dated entries documenting IGA/EASI scores, all prior topical and systemic therapies with exact dates, and the prescribing physician's reasoning for biologic initiation. Missing a single date or drug name is the most common reason PAs are kicked back for more information.

Step 2: California SB 159 assessment. Check whether any required step-therapy drug is contraindicated (e.g., tacrolimus is relatively contraindicated in Netherton syndrome, which can mimic atopic dermatitis). If so, document contraindication explicitly; SB 159 exempts the patient from that step.

Step 3: Concurrent copay card enrollment. Enroll in Dupixent MyWay on the same day the PA is submitted, not after approval. If the PA is approved quickly, the drug ships without a gap. If denied, the copay card is already active for bridge supply while appealing.

Step 4: DMHC IMR as the parallel track. File the IMR request simultaneously with the internal appeal rather than waiting for internal appeal resolution. California law allows concurrent filing, and IMR turnaround (30 days standard, 3 days expedited) is often faster than the insurer's own appeal process.

Sharp Health Plan Contact Information for Dupixent Coverage Questions

Reach Sharp Health Plan member services at the number on the back of your insurance card (typically 1-800-359-2002 for commercial plans or 1-800-684-2320 for Medicare Advantage). Specific questions to ask:

• "Is dupilumab covered under my plan's specialty formulary?"
• "Which pharmacy benefit manager administers my specialty drug benefit?"
• "What are the step therapy requirements for ICD-10 code L20.9 (atopic dermatitis)?"
• "What is the PA turnaround time and how do I check status?"
• "How do I request an expedited review?"

Request a written summary of coverage determination under California Health and Safety Code §1363.1, which requires Sharp to provide clear written explanations of coverage decisions.

Alternatives to Dupixent If Coverage Is Denied Long-Term

If Sharp denies Dupixent through all appeal levels, several FDA-approved alternatives exist for moderate-to-severe atopic dermatitis.

Tralokinumab (Adbry)

Tralokinumab (Adbry) specifically blocks IL-13 and received FDA approval in December 2021 for adults with moderate-to-severe atopic dermatitis. In the ECZTRA-1 trial (N=802), 15.8% of patients achieved IGA 0/1 at week 16 versus 7.1% with placebo (P<0.001). [14] Some payers place Adbry on a different formulary tier than Dupixent, so it may be easier to access under certain Sharp plan designs.

Upadacitinib (Rinvoq) and Abrocitinib (Cibinqo)

Both are oral JAK inhibitors approved for moderate-to-severe atopic dermatitis. The FDA label includes a boxed warning regarding serious infections, malignancy, and cardiovascular events. [15] Some patients prefer an oral option; however, the risk profile means JAK inhibitors are not automatically a simpler alternative. Your prescriber should weigh the boxed warning against the clinical need.

Summary of Key Numbers for Dupixent Coverage Under Sharp Health Plan

| Parameter | Typical Value | |---|---| | PA review time (standard) | 3 to 5 business days | | PA review time (expedited) | 72 hours | | Step therapy drugs typically required | 2 topical agents (TCS + TCI) | | Duration of step therapy trial | 4 to 8 weeks each | | Dupixent MyWay copay cap (commercial) | $0/month | | Internal appeal filing window | 60 days from denial | | IMR standard turnaround | 30 calendar days | | IMR expedited turnaround | 3 business days | | 2025 Medicare Part D OOP cap | $2,000/year |

The single most actionable step a Sharp Health Plan member can take today is to call their dermatologist's office and ask whether a prior authorization has already been submitted, and if so, what the tracking number is.